SSPN-transgenic expression in the sarcoglycanopathy models (SgcaTG, SgcbTG, SgcgTG) revealed that disease pathology was mitigated in the Sgcg, but not Sgca or Sgcb. This evidence concerns the gene SGCB and sarcoglycanopathy.